Bio-Rad Laboratories, Inc.

Informe acción NYSE:BIO

Capitalización de mercado: US$7.7b

Bio-Rad Laboratories Dirección

Dirección controles de criterios 4/4

El CEO de Bio-Rad Laboratories' es Norman Schwartz , nombrado en Jan 2003, tiene una permanencia de 21.25 años. compensación anual total es $7.46M, compuesta por 13.9% salario y 86.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 4.24% de las acciones de la empresa, por valor de $338.72M. La antigüedad media del equipo directivo y de la junta directiva es de 7.8 años y 7 años, respectivamente.

Información clave

Norman Schwartz

Chief Executive Officer (CEO)

US$7.5m

Compensación total

Porcentaje del salario del CEO13.9%
Permanencia del CEO21.3yrs
Participación del CEO4.2%
Permanencia media de la dirección7.9yrs
Promedio de permanencia en la Junta Directiva7.1yrs

Actualizaciones recientes de la dirección

Recent updates

Bio-Rad Laboratories (NYSE:BIO) Has A Pretty Healthy Balance Sheet

Apr 18
Bio-Rad Laboratories (NYSE:BIO) Has A Pretty Healthy Balance Sheet

Bio-Rad: A Lackluster Picks-And-Shovels Life Science Company With A Key Investment Kicker

Apr 14

At US$325, Is Bio-Rad Laboratories, Inc. (NYSE:BIO) Worth Looking At Closely?

Feb 07
At US$325, Is Bio-Rad Laboratories, Inc. (NYSE:BIO) Worth Looking At Closely?

Are Investors Undervaluing Bio-Rad Laboratories, Inc. (NYSE:BIO) By 43%?

Dec 17
Are Investors Undervaluing Bio-Rad Laboratories, Inc. (NYSE:BIO) By 43%?

Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?

Nov 20
Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?

Bio-Rad: Business Returns Aren't Economically Valuable, Sartorius Now A Hindrance

Oct 25

At US$358, Is It Time To Put Bio-Rad Laboratories, Inc. (NYSE:BIO) On Your Watch List?

Oct 02
At US$358, Is It Time To Put Bio-Rad Laboratories, Inc. (NYSE:BIO) On Your Watch List?

We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt

Aug 21
We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt

Bio-Rad: A Cash Flow Returns On Investments Analysis

Aug 10

Are Bio-Rad Laboratories, Inc. (NYSE:BIO) Investors Paying Above The Intrinsic Value?

Jul 30
Are Bio-Rad Laboratories, Inc. (NYSE:BIO) Investors Paying Above The Intrinsic Value?

Is It Too Late To Consider Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?

Jul 04
Is It Too Late To Consider Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?

Does Bio-Rad Laboratories (NYSE:BIO) Have A Healthy Balance Sheet?

May 23
Does Bio-Rad Laboratories (NYSE:BIO) Have A Healthy Balance Sheet?

A Look At The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

May 01
A Look At The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Why Bio-Rad Laboratories, Inc. (NYSE:BIO) Could Be Worth Watching

Apr 04
Why Bio-Rad Laboratories, Inc. (NYSE:BIO) Could Be Worth Watching

Bio-Rad Labs reports Q4 2022 results

Feb 16

Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?

Feb 10
Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?

Calculating The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Jan 20
Calculating The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Bio-Rad: How Efficient Is Its Capital Management? A Deep Look, With Technicals

Jan 04

Why Bio-Rad Laboratories, Inc. (NYSE:BIO) Could Be Worth Watching

Dec 08
Why Bio-Rad Laboratories, Inc. (NYSE:BIO) Could Be Worth Watching

Bio-Rad Labs Non-GAAP EPS of $2.60 misses by $0.17, revenue of $680.8M misses by $1.9M

Oct 27

A Look At The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Oct 14
A Look At The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Will Bio-Rad And Qiagen Merge? I Can't See Any Logic To This Deal

Oct 12

Bio-Rad Laboratories hits 52-week low; down 40% YTD

Sep 19

Is Bio-Rad Laboratories (NYSE:BIO) Using Too Much Debt?

Sep 02
Is Bio-Rad Laboratories (NYSE:BIO) Using Too Much Debt?

Bio-Rad Labs Non-GAAP EPS of $3.38 beats by $0.67, revenue of $691.1M beats by $26.5M

Jul 28

When Should You Buy Bio-Rad Laboratories, Inc. (NYSE:BIO)?

Jul 25
When Should You Buy Bio-Rad Laboratories, Inc. (NYSE:BIO)?

Estimating The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Jul 04
Estimating The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Bio-Rad Laboratories (NYSE:BIO) Has A Rock Solid Balance Sheet

May 02
Bio-Rad Laboratories (NYSE:BIO) Has A Rock Solid Balance Sheet

Bio-Rad Offers Value If You Look

Mar 28

Bio-Rad Laboratories: Relentless Growth Supports A Bullish Outlook

Dec 25

Is Now The Time To Look At Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?

Dec 10
Is Now The Time To Look At Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Norman Schwartz en comparación con los beneficios de Bio-Rad Laboratories?
FechaCompensación totalSalarioIngresos de la empresa
Dec 31 2023US$7mUS$1m

-US$637m

Sep 30 2023n/an/a

-US$159m

Jun 30 2023n/an/a

-US$428m

Mar 31 2023n/an/a

-US$191m

Dec 31 2022US$8mUS$1m

-US$4b

Sep 30 2022n/an/a

-US$6b

Jun 30 2022n/an/a

-US$2b

Mar 31 2022n/an/a

-US$91m

Dec 31 2021US$9mUS$988k

US$4b

Sep 30 2021n/an/a

US$7b

Jun 30 2021n/an/a

US$4b

Mar 31 2021n/an/a

US$4b

Dec 31 2020US$8mUS$987k

US$4b

Sep 30 2020n/an/a

US$4b

Jun 30 2020n/an/a

US$2b

Mar 31 2020n/an/a

US$2b

Dec 31 2019US$7mUS$950k

US$2b

Sep 30 2019n/an/a

US$377m

Jun 30 2019n/an/a

US$905m

Mar 31 2019n/an/a

US$574m

Dec 31 2018US$8mUS$942k

US$366m

Sep 30 2018n/an/a

US$1b

Jun 30 2018n/an/a

US$1b

Mar 31 2018n/an/a

US$767m

Dec 31 2017US$5mUS$922k

US$122m

Compensación vs. Mercado: La compensación total ($USD7.46M) de Norman está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD8.30M).

Compensación vs. Ingresos: La compensación de Norman ha sido consistente con los resultados de la empresa en el último año.


CEO

Norman Schwartz (73 yo)

21.3yrs

Permanencia

US$7,463,878

Compensación

Mr. Norman D. Schwartz was Principal Financial Officer of Bio-Rad Laboratories, Inc. since February 9, 2024 until April 15, 2024 and served as its Interim CFO until February 9, 2024. He serves as Independe...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Norman Schwartz
Chairman21.3yrsUS$7.46m4.24%
$ 328.4m
Andrew Last
Executive VP & COO5.1yrsUS$3.27m0.018%
$ 1.4m
Simon May
Executive VP & President of the Life Science Groupno dataUS$2.09m0.011%
$ 843.4k
Roop Lakkaraju
Executive VP & CFOless than a yearsin datossin datos
Tania DeVilliers
Senior Director2.9yrssin datos0.00019%
$ 14.7k
Yong Chung
Vice President of Investor Relationsno datasin datossin datos
Timothy Ernst
Executive VP7.9yrssin datos0.012%
$ 922.4k
Matthew Werner
Senior Vice President and Chief Compliance & Privacy Officerno datasin datossin datos
Colleen Corey
Executive Vice President of Global Human Resources10.1yrssin datos0.060%
$ 4.7m
Michael Crowley
Executive Vice President of Global Commercial Operations9.4yrsUS$2.68m0.024%
$ 1.9m
Lee Boyd
Senior Vice President of Global Commercial Operations - Asia Pacificno datasin datossin datos
James Barry
Senior Vice President of Global Manufacturingno datasin datossin datos

7.9yrs

Permanencia media

61yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de BIO es experimentado (7.8 años antigüedad media).


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Norman Schwartz
Chairman29.3yrsUS$7.46m4.24%
$ 328.4m
Gregory Hinckley
Lead Independent Director7.1yrsUS$199.25k0.0018%
$ 135.5k
Alice Schwartz
Director Emeritus2.1yrsUS$40.18k11.27%
$ 872.5m
Jeffrey Edwards
Independent Director7.1yrsUS$150.00ksin datos
Arnold Pinkston
Independent Director7.1yrsUS$140.00ksin datos
Melinda Pei
Independent Director7.1yrsUS$195.00ksin datos
Allison Schwartz
Director2.1yrssin datos0.018%
$ 1.4m

7.1yrs

Permanencia media

65yo

Promedio de edad

Junta con experiencia: La junta directiva de BIO se considera experimentada (7 años de antigüedad promedio).